Results overview: Found 4 records in 0.01 seconds.
Articles, 4 records found
Articles 4 records found  
1.
12 p, 755.8 KB A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly / Trainer, Peter J (Department of Endocrinology) ; Newell-Price, John D C (Royal Hallamshire Hospital) ; Ayuk, John (Medicine Endocrinology) ; Aylwin, Simon J B (King's College Hospital) ; Rees, Aled (Neuroscience and Mental Health Research Institute) ; Drake, William (Department of Endocrinology) ; Chanson, Philippe (Inserm 1185) ; Brue, Thierry (APHM) ; Webb, Susan M (Institut d'Investigació Biomèdica Sant Pau) ; Fajardo, Carmen (Servicio de Endocrinología) ; Aller, Javier (Endocrinology Department) ; McCormack, Ann I (Garvan Institute of Medical Research and St Vincent's Hospital) ; Torpy, David J (Royal Adelaide Hospital) ; Tachas, George (Antisense Therapeutics Limited) ; Atley, Lynne (Antisense Therapeutics Limited) ; Ryder, David (Manchester Academic Health Science Centre (MAHSC) Clinical Trials Unit) ; Bidlingmaier, Martin (Endocrine Laboratory) ; Universitat Autònoma de Barcelona
ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. [...]
2018 - 10.1530/EJE-18-0138
European journal of endocrinology, Vol. 179 (may 2018) , p. 97-108  
2.
10 p, 556.3 KB Quality of Life in Patients With Cushing's Disease / Santos, Alicia (Institut d'Investigació Biomèdica Sant Pau) ; Resmini, Eugenia (Institut d'Investigació Biomèdica Sant Pau) ; Martínez Momblán, Mª Antonia (Institut d'Investigació Biomèdica Sant Pau) ; Valassi, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Martel, Luciana (Institut d'Investigació Biomèdica Sant Pau) ; Webb, Susan M. (Universitat Autònoma de Barcelona. Departament de Medicina)
Cushing's disease (and by extension, Cushing's syndrome) is a rare disease due to a chronic cortisol excess, which usually has an important impact on quality of life (QoL). It can lead to numerous comorbidities that can interfere with daily life, as fatigability, myopathy, bone loss and fragility, increased cardiovascular risk, depression, and cognitive alterations. [...]
2019 - 10.3389/fendo.2019.00862
Frontiers in Endocrinology, Vol. 10 (december 2019)  
3.
7 p, 744.3 KB Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome : Preliminary Study / Santos, Alicia (Institut d'Investigació Biomèdica Sant Pau) ; Granell, Esther (Institut d'Investigació Biomèdica Sant Pau) ; Gómez Ansón, Beatriz (Institut d'Investigació Biomèdica Sant Pau) ; Crespo, Iris (Institut d'Investigació Biomèdica Sant Pau) ; Pires, Patricia (INNDACYT, Hospitalet de Llobregat) ; Vives-Gilabert, Yolanda (INNDACYT, Hospitalet de Llobregat) ; Valassi, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Webb, Susan M. (Institut d'Investigació Biomèdica Sant Pau) ; Resmini, Eugenia (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Cushing's syndrome (CS) has repeatedly been associated with hippocampal volume reductions, while little information is available on the amygdala, another structure rich in glucocorticoid receptors. The aim of the study was to analyze amygdala volume in patients with CS and its relationship with anxiety, depression, and hormone levels. [...]
2017 - 10.1155/2017/2061935
BioMed Research International, Vol. 2017 (may 2017)  
4.
9 p, 572.2 KB Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly : data from the PRIMARYS study / Caron, Philippe J. (Department of Endocrinology and Metabolic Diseases, Centre Hospitalier Universitaire Larrey) ; Bevan, John S. (Department of Endocrinology, Aberdeen Royal Infirmary) ; Petersenn, Stephan (ENDOC Center for Endocrine Tumors, Hamburg, Germany) ; Houchard, Aude (Ipsen) ; Sert, Caroline (Ipsen) ; Webb, Susan M. (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona ; Centro de Investigación Biomédica en Red de Enfermedades Raras
To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients with acromegaly. [...]
2015 - 10.1007/s11102-015-0693-y
Pituitary, Vol. 19 (november 2015) , p. 149-157  

See also: similar author names
59 Webb, S.
10 Webb, S. M.
12 Webb, S. M. q (Susan M.),
1 Webb, S.M.
1 Webb, Samuel
1 Webb, Susan
2 Webb, Susan M
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.